tailieunhanh - WHO Model List of Essential Medicines 16th list (updated) March 2010 

Making vocational degree qualifications comparable and easily readable is at the heart of the Bologna Process. Methods of achieving this based purely on duration of study are fallible and give little information as to how graduates will perform in the workplace. A more robust outcome-based approach was developed by the Tuning Project (), a sector-wide project to agree learning outcomes/competences for all disciplines in Higher Education in Europe. Initiated in 000, the Tuning Project is led by Julia González (University of Deusto) and Robert Wagenaar (University of Groningen). Several disciplines, including nursing, developed learning outcomes during the initial phases. | WHO Model List of Essential Medicines 16th list updated March 2010 Status of this document This is a reprint of the text on the WHO Medicines web site http medicines publications essentialmedicines en The published material is being distributed without warranty of any kind either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. 16th edition updated Essential Medicines WHO Model List March 2010 Explanatory Notes The core list presents a list of minimum medicine needs for a basic health-care system listing the most efficacious safe and cost-effective medicines for priority conditions. Priority conditions are selected on the basis of current and estimated future public health relevance and potential for safe and cost-effective treatment. The complementary list presents essential medicines for priority diseases for which specialized diagnostic or monitoring facilities and or specialist medical care and or specialist training are needed. In case of doubt medicines may also be listed as complementary on the basis of consistent higher costs or less attractive costeffectiveness in a variety of settings. The square box symbol is primarily intended to indicate similar clinical performance within a pharmacological class. The listed medicine should be the example of the class for which there is the best evidence for effectiveness and safety. In some cases this may be the first medicine that is licensed for marketing in other instances subsequently licensed compounds may be safer or more effective. Where there is no difference in terms of efficacy and safety data the listed medicine should be the one that is generally available at the lowest price based on international drug price information sources. Not all square boxes are applicable to medicine selection for children see the second EMLc for details. .

TỪ KHÓA LIÊN QUAN
TÀI LIỆU MỚI ĐĂNG
crossorigin="anonymous">
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.